お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
989724

臨床腫瘍次世代シーケンシング (NGS) の市場動向・市場シェア・市場規模の予測 (2021-2028年):ワークフロー技術 (WGS・WES)・用途 (スクリーニング・コンパニオン診断)・エンドユーザー・地域別

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow, By Technology (WGS, WES), By Application (Screening, Companion Diagnostics), By End-use, And Segment Forecasts, 2021 - 2028

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 155 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.25円
臨床腫瘍次世代シーケンシング (NGS) の市場動向・市場シェア・市場規模の予測 (2021-2028年):ワークフロー技術 (WGS・WES)・用途 (スクリーニング・コンパニオン診断)・エンドユーザー・地域別
出版日: 2021年02月10日
発行: Grand View Research, Inc.
ページ情報: 英文 155 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の臨床腫瘍次世代シーケンシング (NGS) の市場規模は予測期間中14.70%のCAGRで推移し、2028年には8億9261万米ドルの規模に成長すると予測されています。NGS技術の進歩、コンパニオン診断および個別化医療の高い採用率などの要因が同市場の成長を推進しています。また、リキッドバイオプシーのためのNGSの有用性の高まりがさらなる収益成長に貢献する見通しです。

当レポートでは、世界の臨床腫瘍次世代シーケンシング (NGS) の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制・償還環境、市場規模の推移・予測、技術・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 調査手法・調査範囲

第2章 エグゼクティブサマリー

第3章 市場可変因子・動向・展望

  • 市場の分類・範囲
  • 事業部門の動向
  • 市場可変因子の分析
  • SWOT分析
  • COVID-19の影響
  • 償還環境
  • 規制・政治環境

第4章 競合環境・ベンダー情勢

  • 戦略的枠組み
  • 市場参入事業者の分類

第5章 市場予測・動向分析:技術別

  • 全ゲノムシーケンス
  • 全エクソームシーケンス
  • ターゲットシーケンシング・リシーケンシング

第6章 市場予測・動向分析:ワークフロー別

  • NGSプレシーケンス
  • NGSシーケンス
  • NGSデータ分析

第7章 市場予測・動向分析:用途別

  • スクリーニング
    • 散発性がん
  • コンパニオン診断
  • その他

第8章市場予測・動向分析:エンドユーザー別

  • 病院
  • クリニック
  • ラボ

第9章 市場予測・動向分析:地域・主要国別

  • 市場シェア実績・予測
  • 市場規模の推移・予測
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第10章 企業プロファイル

  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies
  • Thermo Fisher Scientific Inc.
  • Myriad Genetics, Inc.
  • Beijing Genomics Institute (BGI)
  • Qiagen NV
  • Perkin Elmer, Inc.
  • Pacific Bioscience, Inc.
  • Partek, Inc.
  • Foundation Medicine Inc.
  • Oxford Nanopore Technologies Ltd.
  • Paradigm Diagnostics, Inc
  • Caris Life Sciences
  • Eurofins Scientific S.E.
  • Perkin Elmer
図表

List of Tables

  • TABLE 1 Healthcare expenditure levels, 2012
  • TABLE 2 Cancer Incidence and Mortality, By Region, 2018
  • TABLE 3 Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
  • TABLE 4 FDA-Approved NGS Tumour-Profiling Tests for Companion Diagnostics
  • TABLE 5 Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
  • TABLE 6 North America clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 7 North America clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 8 North America clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 9 North America clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 10 North America clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 11 The U.S. clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 12 The U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 13 The U.S. clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 14 The U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 15 The U.S. clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 16 Canada clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 17 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 18 Canada clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 19 Canada clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 20 Canada clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 21 Europe clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 22 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 23 Europe clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 24 Europe clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 25 Europe clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 26. Germany clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 27. Germany clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 28. Germany clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 29. Germany clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 30. Germany clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 31. The U.K. clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 32. The U.K. clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 33. The U.K. clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 34. The U.K. clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 35. The U.K. clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 36. France clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 37. France clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 38. France clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 39. France clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 40. France clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 41. Italy clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 42. Italy clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 43. Italy clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 44. Italy clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 45. Italy clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 46. Spain clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 47. Spain clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 48. Spain clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 49. Spain clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 50. Spain clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million) 
  • TABLE 51. Asia-Pacific clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 52. Asia-Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 53. Asia-Pacific clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 54. Asia-Pacific clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 55. Asia-Pacific clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 56. Japan clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 57. Japan clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 58. Japan clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 59. Japan clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 60. Japan clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 61. China clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 62. China clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 63. China clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 64. China clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 65. China clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 66. India clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 67. India clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 68. India clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 69. India clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 70. India clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 71. South Korea clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 72. South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 73. South Korea clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 74. South Korea clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 75. South Korea clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 76. Australia clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 77. Australia clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 78. Australia clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 79. Australia clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 80. Australia clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 81. Latin America clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 82. Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 83. Latin America clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 84. Latin America clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 85. Latin America clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 86. Brazil clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 87. Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 88. Brazil clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 89. Brazil clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 90. Brazil clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 91. Mexico clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 92. Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 93. Mexico clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 94. Mexico clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 95. Mexico clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 96. Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 97. Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 98. Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 99. Middle East & Africa clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 100. Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 101. South Africa clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 102. South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 103. South Africa clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 104. South Africa clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 105. South Africa clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)
  • TABLE 106. Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2017 - 2028 (USD Million)
  • TABLE 107. Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2017 - 2028 (USD Million)
  • TABLE 108. Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 109. Saudi Arabia clinical oncology NGS screening market estimates & forecasts, by application, 2017 - 2028 (USD Million)
  • TABLE 110. Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2017 - 2028 (USD Million)

List of Figures

  • FIG. 1 Market snapshot
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Penetration & growth prospect mapping for application, 2020
  • FIG. 11 Penetration & growth prospect mapping for prominent industry players, 2020
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
  • FIG. 14 Cost per genome
  • FIG. 15 Expected rise in expenditure for cancer treatment (USD Billion)
  • FIG. 16 Number of new cancer cases in the World, 2018
  • FIG. 17 Market restraint relevance analysis (Current & future impact)
  • FIG. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 19 Porter's Five Forces Analysis
  • FIG. 20 Strategy framework
  • FIG. 21 Participant categorization
  • FIG. 22 Clinical oncology NGS market: Technology outlook key takeaways
  • FIG. 23 Clinical oncology NGS market: Technology movement analysis
  • FIG. 24 Whole genome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • FIG. 25 Whole exome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • FIG. 26 Targeted sequencing and resequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • FIG. 27 Clinical oncology NGS market: Workflow outlook key takeaways
  • FIG. 28 Clinical oncology NGS market: Workflow movement analysis
  • FIG. 29 NGS pre-sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • FIG. 30 NGS sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • FIG. 31 NGS data analysis for clinical oncology market, 2017 - 2028 (USD Million)
  • FIG. 32 Clinical oncology NGS market: Application outlook key takeaways
  • FIG. 33 Clinical oncology NGS market: Application movement analysis
  • FIG. 34 Screening clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 35 Sporadic cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 36 Lifetime cancer risks for common cancers
  • FIG. 37 Inherited cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 38 Companion diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 39 Other diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 40 Clinical oncology NGS market: End use outlook key takeaways
  • FIG. 41 Clinical oncology NGS market: End use movement analysis
  • FIG. 42 Hospitals clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 43 Clinics clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 44 Laboratories clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 45 Regional market place: Key takeaway
  • FIG. 46 Clinical oncology NGS market: Regional outlook, 2018 & 2025
  • FIG. 47 North America clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 48 The U.S. clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 49 Canada clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 50 Europe clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 51 Germany clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 52 The U.K. clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 53 France clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 54 Italy clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 56 Asia-Pacific clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 57 Japan clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 58 China clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 55 Spain clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 59 India clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 60 South Korea clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 61 Australia clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 62 Latin America clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 63 Brazil clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 64 Mexico clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 65 Middle East & Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 66 South Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 67 Saudi Arabia clinical oncology NGS market, 2017 - 2028 (USD Million)
  • FIG. 68 Key companies profiled
目次
Product Code: GVR-3-68038-791-9

Clinical Oncology NGS Market Growth & Trends

The global clinical oncology next generation sequencing market size is expected to reach USD 892.61 million by 2028 registering a CAGR of 14.70%, according to a new report by Grand View Research, Inc. Technological advancements in next-generation sequencing coupled with high adoption of companion diagnostics and personalized medicine drive the global market growth.

In addition, a rise in the utility of next generation sequencing (NGS) for liquid biopsy is expected to increase revenue generation in the market. NGS is employed to sequence circulating tumor DNA (ctDNA) for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive monitoring of tumors.

Moreover, a rise in market competitiveness, growth in oncology diagnostics spending, and increasing research activities to develop solutions that can potentially be used for clinical oncology drive market progression. For instance, in January 2021, Spectrum Solutions, LLC collaborated with the UCLA School of Dentistry on saliva-based NGS liquid biopsy research, which would be used for early diagnosis of Non-Small Cell Lung Cancer (NSCLC).

North America dominated the global market in 2020 owing to multiple initiatives taken by various government bodies in the region to screen and prevent cancer, such as Cancer Prevention and Control Research Network, a flagship program by the CDC. Asia Pacific is projected to be the fastest-growing regional market over the forecast period owing to continuous reforms in the pharmaceutical and life sciences industries in the region.

Key players in this market have undertaken strategic alliances to strengthen their market position. For example, in March 2020, Thermo Fisher Scientific signed an agreement with Janssen Biotech, Inc. for the development of CDx for tumor management. Under the agreement, Janssen Research & Development, LLC would validate multiple biomarkers to be used with Thermo Fisher's Oncomine Dx target test for identification of patients with NSCLC

Clinical Oncology NGS Market Report Highlights

  • Targeted sequencing & resequencing accounted for the largest market share in 2020 owing to the high adoption of targeted gene panels for oncology diagnostics
  • Moreover, the discovery of novel cancer biomarkers further boosts the development of targeted sequencing oncology panels
  • Whole-Genome Sequencing (WGS) is projected to register the fastest growth rate from 2021 to 2028 as the technology offers a complete genomic survey of the tumor genome
  • This helps in the generation of a detailed map of indels, copy number changes, Single Nucleotide Variations (SNV), and complex structural rearrangements with a single assay
  • Companion diagnostics is projected to be the fastest-growing application segment from 2021 to 2028 owing to the high adoption and benefits offered by the technology
  • Therefore, major market participants focus on innovative R&D in companion diagnostics to gain approval for novel tests
  • For instance, in August 2020, the FDA approved Guardant360 CDx assay; an NGS-based liquid biopsy CDx to identify Epidermal Growth Factor Receptor (EGFR) gene mutations in metastatic NSCLC

Table of Contents

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Business segment trends
    • 3.2.1 Penetration & Growth Prospect Mapping For Application, 2020
    • 3.2.2 Penetration & Growth Prospect Mapping For Prominent Industry Players, 2020
  • 3.3 Market variables analysis
      • 3.3.1Market driver analysis
      • 3.3.1.1 Decrease in costs for genetic sequencing
      • 3.3.1.2 Advancements in the field of personalized medicine
      • 3.3.1.3 Rise in competition amongst prominent market entities
      • 3.3.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
      • 3.3.1.5 Rise in prevalence of cancer
      • 3.3.1.6 Growing adoption of NGS over single gene testing
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Lack of computational efficiency for data management
      • 3.3.2.2 Non-value based NGS reimbursement policy
  • 3.4 Business environment analysis tools
    • 3.4.1 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
      • 3.4.2Porter's five forces analysis
  • 3.5 Impact of COVID-19 on Market Growth
  • 3.6 Next-Generation Sequencing Reimbursement Environment
  • 3.7 Regulatory and Political Environment

Chapter 4 Competitive & Vendor Landscape

  • 4.1 Strategy Framework
  • 4.2 Market Participation Categorization

Chapter 5 Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 5.1 Clinical Oncology NGS Market: Technology movement analysis
  • 5.2 Whole Genome Sequencing
      • 5.2.1Whole genome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • 5.3 Whole Exome Sequencing
    • 5.3.1 Whole exome sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • 5.4 Targeted Sequencing & Resequencing
    • 5.4.1 Targeted sequencing and resequencing for clinical oncology market, 2017 - 2028 (USD Million)

Chapter 6 Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 6.1 Clinical Oncology NGS Market: Workflow Movement Analysis
  • 6.2 NGS Pre-Sequencing
    • 6.2.1 NGS pre-sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • 6.3 NGS Sequencing
    • 6.3.1 NGS sequencing for clinical oncology market, 2017 - 2028 (USD Million)
  • 6.4 NGS Data Analysis
    • 6.4.1 NGS data analysis for clinical oncology market, 2017 - 2028 (USD Million)

Chapter 7 Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 7.1 Clinical Oncology NGS Market: Application Movement Analysis
  • 7.2 Screening
    • 7.2.1 Screening clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 7.2.2 Sporadic Cancer
      • 7.2.2.1 Sporadic cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 7.2.3Inherited cancer
      • 7.2.3.1 Inherited cancer screening clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 7.3 Companion Diagnostics
    • 7.3.1 Companion diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 7.4 Other Diagnostics
    • 7.4.1 Other diagnostics clinical oncology NGS market, 2017 - 2028 (USD Million)

Chapter 8 Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

  • 8.1 Clinical Oncology NGS Market: End Use Movement Analysis
  • 8.2 Hospitals
    • 8.2.1 Hospitals clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 8.3 Clinics
    • 8.3.1 Clinics clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 8.4 Laboratories
    • 8.4.1 Laboratories clinical oncology NGS market, 2017 - 2028 (USD Million)

Chapter 9 Clinical Oncology Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Technology, Workflow, Application, & End Use

  • 9.1 Clinical Oncology NGS Market Share By Regional, 2018 & 2025
  • 9.2 North America
    • 9.2.1 North America clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.2.2 The U.S.
      • 9.2.2.1 The U.S. clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.2.3Canada
      • 9.2.3.1Canada clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.3.3 The U.K.
      • 9.3.3.1 The U.K. clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.3.4 France
      • 9.3.4.1 France clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.3.5 Italy
      • 9.3.5.1 Italy clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.3.6Spain
      • 9.3.6.1Spain clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 9.4 Asia Pacific
      • 9.4.1Asia-Pacific clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.4.2Japan
      • 9.4.2.1 Japan clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.4.3China
      • 9.4.3.1 China clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.4.4India
      • 9.4.4.1 India clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.4.5South Korea
      • 9.4.5.1 South Korea clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.4.6Australia
      • 9.4.6.1 Australia clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.5.2Brazil
      • 9.5.2.1 Brazil clinical oncology NGS market, 2017 - 2028 (USD Million)
      • 9.5.3Mexico
      • 9.5.3.1 Mexico clinical oncology NGS market, 2017 - 2028 (USD Million)
  • 9.6 Middle East & Africa (MEA)
    • 9.6.1 Middle East & Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa clinical oncology NGS market, 2017 - 2028 (USD Million)
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Saudi Arabia clinical oncology NGS market, 2017 - 2028 (USD Million)

Chapter 10 Clinical Oncology NGS Market: Company Profiles

  • 10.1 Key Companies Profiled
  • 10.2 Illumina, Inc.
    • 10.2.1 Company overview
      • 10.2.1.1Financial performance
    • 10.2.2 Product benchmarking
    • 10.2.3 Strategic initiatives
  • 10.3 F. Hoffmann-La Roche Ltd
    • 10.3.1 Company overview
      • 10.3.1.1Financial performance
    • 10.3.2 Product benchmarking
    • 10.3.3 Strategic initiatives
  • 10.4 Agilent Technologies
    • 10.4.1 Company overview
    • 10.4.2 Financial performance
    • 10.4.3 Product benchmarking
    • 10.4.4 Strategic initiatives
  • 10.5 Thermo Fisher Scientific Inc.
    • 10.5.1 Company overview
    • 10.5.2 Financial performance
    • 10.5.3 Product benchmarking
    • 10.5.4 Strategic initiatives
  • 10.6 Myriad Genetics, Inc.
    • 10.6.1 Company overview
    • 10.6.2 Financial performance
    • 10.6.3 Product benchmarking
    • 10.6.4 Strategic initiatives
  • 10.7 Beijing Genomics Institute (BGI)
      • 10.7.1Company overview
      • 10.7.2Financial performance
      • 10.7.3Product benchmarking
      • 10.7.4Strategic initiatives
  • 10.8 Qiagen NV
    • 10.8.1 Company overview
    • 10.8.2 Financial performance
    • 10.8.3 Product benchmarking
    • 10.8.4 Strategic initiatives
  • 10.9 Perkin Elmer, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Financial performance
    • 10.9.3 Product benchmarking
    • 10.9.4 Strategic initiatives
  • 10.10 Pacific Bioscience, Inc.
    • 10.10.1 Company overview
    • 10.10.2 Financial performance
    • 10.10.3 Product benchmarking
    • 10.10.4 Strategic initiatives
  • 10.11 Partek, Inc.
    • 10.11.1 Company overview
    • 10.11.2 Financial performance
    • 10.11.3 Product benchmarking
    • 10.11.4 Strategic initiatives
  • 10.12 Foundation Medicine Inc.
    • 10.12.1 Company overview
    • 10.12.2 Financial performance
    • 10.12.3 Product benchmarking
    • 10.12.4 Strategic Initiatives
  • 10.13 Oxford Nanopore Technologies Ltd.
    • 10.13.1 Company overview
    • 10.13.2 Financial performance
    • 10.13.3 Product benchmarking
    • 10.13.4 Strategic Initiatives
  • 10.14 Paradigm Diagnostics, Inc
    • 10.14.1 Company overview
    • 10.14.2 Financial performance
    • 10.14.3 Product benchmarking
    • 10.14.4 Strategic initiatives
  • 10.15 Caris Life Sciences
    • 10.15.1 Company overview
    • 10.15.2 Financial performance
    • 10.15.3 Product benchmarking
    • 10.15.4 Strategic Initiatives
  • 10.16 Eurofins Scientific S.E.
    • 10.16.1 Company overview
    • 10.16.2 Financial performance
    • 10.16.3 Product benchmarking
    • 10.16.4 Strategic initiatives
  • 10.17 Perkin Elmer
    • 10.17.1 Company overview
    • 10.17.2 Financial performance
    • 10.17.3 Product benchmarking
    • 10.17.4 Strategic initiatives
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.